Medical Director -Women's Hormone Therapy

About Medivant Healthcare

Medivant Healthcare is an FDA-registered 503B pharmaceutical manufacturer with over $40M invested in CGMP‑compliant facilities to produce pharma‑grade compounded medications. We are launching the first prefilled syringe (PFS) testosterone product line designed for both men and women—including the first‑ever microdose injectable testosterone specifically formulated for female patients.

The Medical Director — Women’s Health & Hormone Therapy will serve as the clinical face of Medivant Healthcare to the physician community. This role is responsible for building and leading the company’s medical affairs function for the testosterone PFS portfolio. The Medical Director will oversee Key Opinion Leader (KOL) development, Medical Advisory Board strategy, CME initiatives, clinical protocol development, conference engagement, and compliance governance.

This position ensures that all medical communications and educational activities adhere strictly to 503B regulatory standards. This is a foundational leadership role responsible for shaping clinical strategy, category development, and long‑term evidence generation.

• Develop and execute national KOL strategy, recruiting and managing 50–100+ physician leaders, beginning in Wave 1 launch cities (Phoenix, Denver, Seattle, Portland, Austin).
• Establish and chair a National Medical Advisory Board (8–12 members) and build a Clinical Faculty Network (30–50 members).
• Lead quarterly advisory board meetings and translate insights into product and go‑to‑market strategy.
• Partner with accredited CME providers (e.g., Medscape, ACOG, Pri‑Med) to develop educational modules on testosterone deficiency in women.
• Oversee clinical content for Doximity campaigns, sponsored publications, and conference materials.
• Lead medical presence at national conferences including NAMS, ISSWSH, ACOG, A4M, and regional OBGYN meetings.
• Develop evidence‑based prescribing guidelines, dosing protocols, and patient monitoring templates for:
  • Women’s microdose PFS (1.25 mg, 2.5 mg, 5 mg, 10 mg weekly doses)
  • Men’s PFS (25 mg, 50 mg, 100 mg)
• Provide clinical governance for nurse educator outreach to ensure all communications remain within 503B boundaries (factual product description and workflow education only).
• Review and approve medical, marketing, and training materials to ensure compliance with 503B promotional restrictions.
• Support development of a long‑term research agenda, including investigator‑initiated studies and retrospective chart reviews.

• Medical Advisory Board operational by Month 2
• 15–20 active KOL prescribers in Wave 1 cities by Month 3
• National CME module launched by Month 4
• 50+ engaged KOLs across 10+ metropolitan areas by Month 6
• Clinical protocols published and distributed to pharmacy and clinic partners
• Prescriber conversion metrics tracked by channel
• Company presence established at 3–4 major conferences with KOL‑led presentations

• MD or DO with active U.S. medical license (in good standing)
• Clinical background in OBGYN, reproductive endocrinology, menopause medicine, sexual health, or endocrinology
• Minimum 5 years of clinical practice with direct experience prescribing hormone therapy to women
• Established relationships within menopause and women’s health physician communities (e.g., NAMS, ISSWSH, Biote network, or equivalent)
• Strong understanding of pharmaceutical or 503B medical affairs functions
• Thorough understanding of 503B compliance requirements and medical communication boundaries
• Comfortable presenting to physician audiences at national conferences

• NAMS Certified Menopause Practitioner (NCMP) designation
• Prior experience as Medical Director, VP Medical Affairs, or equivalent leadership role
• Demonstrated KOL network development and advisory board management experience
• Experience with CME program development and accreditation processes
• Published research in women’s hormone therapy, testosterone, or sexual health
• Familiarity with Biote practitioner network and pellet therapy landscape
• Experience prescribing and managing DEA Schedule III controlled substances

• Build a medical affairs function from the ground up for a new therapeutic category
• Shape the women’s injectable testosterone market with no incumbent FDA‑approved products
• Join a manufacturer with $40M+ invested in FDA‑registered CGMP facilities
• Direct access to executive leadership and cross‑functional strategic decision‑making
• Opportunity for equity participation